#Pharmaceuticals

Johnson & Johnson Reports Stronger-Than-Expected First-Quarter Profit Amid Stelara Sales Shortfall

Despite disappointing sales of its Stelara drug, Johnson & Johnson's first-quarter profits exceeded analyst expectations, reflecting the company's ongoing efforts in a challenging market.